<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000621.v1.p1" parentStudy="phs000621.v1.p1" createDate="2013-05-17" modDate="2013-07-08">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Richard Weinshilboum, MD</td><td>Mayo Clinic</td></tr>
		<tr><td>Funding Source</td><td>R01 CA132780</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genome Wide Association Studies in ECOG 2997 Trial</StudyNameEntrez>
	<StudyNameReportPage>Genome Wide Association Studies in ECOG 2997 Trial</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Clinical Trial</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The ECOG 2997 trial was a randomized controlled trial for patients with previously untreated CLL comparing fludarabine monotherapy to the combination of fludarabine and cyclophosphamide. The initial clinical findings of this study were published in the Journal of Clinical Oncology in 2007 (JCO 25:793-8). Additional laboratory studies have also published (JCO 25:799-804).</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>DISEASE CHARACTERISTICS:<br/> <ul> <li>Diagnosis of chronic lymphocytic leukemia (CLL) of any stage as defined by the following:</li> <li>Peripheral blood absolute lymphocyte count greater than 5,000/mm^3 within 14 days prior to study</li> <li>Lymphocytes must be small to moderate size with no more than 55% prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically</li> <li>Phenotypically characterized as B-CLL</li> <li>Must have one of the following characteristics indicating need for chemotherapy:</li> <li>Progressive marrow failure (hemoglobin less than 10 g/dL and/or platelet count less than 100,000/mm^3)</li> <li>Progressive lymphocytosis with an increase of more than 50% over a 2 month period or anticipated doubling time of less than 6 months</li> <li>Massive (i.e., greater than 6 cm below left costal margin) or progressive splenomegaly</li> <li>Massive nodes or clusters (i.e., greater than 10 cm in longest diameter) or progressive adenopathy</li> <li>At least 10% weight loss within 6 months of study</li> <li>Extreme fatigue</li> <li>Fevers greater than 100.5 degrees F for 2 weeks without evidence of infection</li> <li>Night sweats without evidence of infection</li> <li>No autoimmune anemia or autoimmune thrombocytopenia</li> </ul> </p> <p>PATIENT CHARACTERISTICS:</p> <p>Age:<br/> <ul> <li>18 and over</li> </ul> </p> <p>Performance status:<br/> <ul> <li>ECOG 0-2</li> </ul> </p> <p>Life expectancy:<br/> <ul> <li>Not specified</li> </ul> </p> <p> Hematopoietic:<br/> <ul> <li>See Disease Characteristics</li> </ul> </p> <p> Hepatic:<br/> <ul> <li>Bilirubin no greater than 2 mg/dL unless secondary to tumor</li> </ul> </p> <p> Renal:<br/> <ul> <li>Creatinine no greater than 2.0 mg/dL</li> <li>Creatinine clearance at least 40 mL/min if creatinine is greater than 1.5 mg/dL</li> </ul> </p> <p> Other:<br/> <ul> <li>No other prior or concurrent malignancy within the past 2 years except basal cell carcinoma of the skin or carcinoma in situ of the cervix</li> <li>No active infection requiring oral or intravenous antibiotics</li> <li>Not pregnant or nursing</li> <li>Fertile patients must use effective contraception</li> </ul> </p> <p>PRIOR CONCURRENT THERAPY:</p> <p>Biologic therapy:<br/> <ul> <li>Not specified</li> </ul> </p> <p>Chemotherapy:<br/> <ul> <li>No prior cytotoxic chemotherapy</li> </ul> </p> <p> Endocrine therapy:<br/> <ul> <li>No prior steroid treatment for CLL</li> </ul> </p> <p>Radiotherapy:<br/> <ul> <li>Not specified</li> </ul> </p> <p>Surgery:<br/> <ul> <li>Not specified</li> </ul> </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="17903304"/>
		</Publication>
		<Publication>
			<Pubmed pmid="39810"/>
		</Publication>
		<Publication>
			<Pubmed pmid="21803850"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17283364"/>
		</Publication>
		<Publication>
			<Pubmed pmid="17283363"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Leukemia, Lymphoid"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Richard Weinshilboum, MD</AttName>
			<Institution>Mayo Clinic</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>R01 CA132780</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>The ECOG 2997 trial was a randomized controlled trial for patients with previously untreated CLL comparing fludarabine monotherapy to the combination of fludarabine and cyclophosphamide. The initial clinical findings of this study were published in the Journal of Clinical Oncology in 2007 (JCO 25:793-8). Additional laboratory studies have also published (JCO 25:799-804). The present project explore the relationship between GWAS and trial outcomes.</p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="HMB-PUB-MDS" longName="Health/Medical/Biomedical (PUB, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000621.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
               http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000621.v1.p1
            </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000621.v1.p1" FileName="eNCI_0169_DUC_07.03.2013.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Health/Medical/Biomedical (PUB, MDS)</ConsentName>
        <ConsentAbbrev>HMB-PUB-MDS</ConsentAbbrev>
        <UseLimitation>Use of this data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry. Requestor agrees to make results of studies using the data available to the larger scientific community. Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
